Breast Cancer: Current Research
Open Access

Research Article

Delaying Radiotherapy and Risk of Recurrences in Patients with Breast Cancer Stage I And II. A Retrospective Observational Study

Cobos-Campos Raquel¹ and Lasso-Varela Aurora^2*

¹Health Research Institute, Integrated Health Organization Araba (University Hospital), José Achótegui Street, Vitoria-Gasteiz, Álava, Spain

²Oncology Radiotherapy Service, Cruces University Hospital, Cruces square, Barakaldo, Vizkaya, Spain

*Corresponding Author:

Aurora Lasso-Varela
Cruces University Hospital
Cruces Square
1248903 Barakaldo, Vizkaya
Tel: 946006398
E-mail: mariaaurora.lassovarela@osakidetza.net

Received date: November 08, 2016; Accepted date: November 23, 2016; Published date: November 28, 2016

Citation: Raquel CC, Aurora LV (2016) Delaying Radiotherapy and Risk of Recurrences in Patients with Breast Cancer Stage I And II. A Retrospective Observational Study. Breast Can Curr Res 1:116. doi:10.4172/2572-4118.1000116

Copyright: © 2016 Raquel CC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Objectives: There is no consensus about the implications of the delay of RT beginning in the incidence of recurrences and mortality of patients with breast cancer. We carried out a retrospective study to assess if the delay of RT beginning can increase the risk of recurrences and mortality.

Methods: We conducted a retrospective observational study including women with a primary diagnosis of breast cancer stage I or II, between January 2003 and December 2008. All patients received surgery, RT and adjuvant chemotherapy, and were followed for a 5 years after diagnosis. Data was obtained from the medical records. The incidence of recurrence and mortality was assessed by logistic regression adjusting for variables that might affect the prognosis of the disease (age, hormone receptors, lymph node involvement, type of chemotherapy, hormone therapy, etc.), and was expressed with the Odds Ratio (OR).

Results: We have not found association between the risk of relapse and delay of RT starting (OR 2.819; 95% CI 0.635-12.506, p=0.173). We have not found association between the risk of mortality by all cause and delay of RT starting (OR 0.993; 95% CI 0.210-4.407, p=0.961).

Conclusions: In view of the results obtained, delaying the start of RT does not seem to increase the risk of recurrences or mortality.

Keywords